​Genus announces the appointment of key opinion leaders Drs. Helen Sabzevari, former head of Immunotherapy at EMD and Ralph Weichselbaum, Professor at University of Chicago, as members of the Genus Scientific Advisory Board.

​Genus Oncology collaborates with leaders in leukemia research at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center on an investigator-initiated Phase 1b/2a trial of GO-203 in combination with Decitabine for the treatment of patients with relapsed/refractory AML.